BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 411 filers reported holding BIO-TECHNE CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,796,754 | -7.8% | 106,362 | -9.0% | 0.01% | -8.3% |
| Q2 2023 | $9,542,792 | -8.8% | 116,903 | -17.1% | 0.01% | -20.0% |
| Q1 2023 | $10,464,203 | +68.7% | 141,046 | +88.4% | 0.02% | +50.0% |
| Q4 2022 | $6,204,314 | -100.0% | 74,859 | +27.2% | 0.01% | -63.0% |
| Q3 2022 | $16,715,388,000 | +56.2% | 58,857 | +90.7% | 0.03% | +58.8% |
| Q2 2022 | $10,700,084,000 | +3.0% | 30,868 | +28.7% | 0.02% | +21.4% |
| Q1 2022 | $10,383,433,000 | -33.2% | 23,978 | -20.2% | 0.01% | -36.4% |
| Q4 2021 | $15,543,998,000 | +8.6% | 30,046 | +1.8% | 0.02% | +10.0% |
| Q3 2021 | $14,308,868,000 | +158.8% | 29,529 | +140.5% | 0.02% | +185.7% |
| Q2 2021 | $5,529,193,000 | +60.3% | 12,280 | +35.9% | 0.01% | +40.0% |
| Q1 2021 | $3,449,974,000 | +83.8% | 9,033 | +52.8% | 0.01% | +66.7% |
| Q4 2020 | $1,877,356,000 | +72.2% | 5,912 | +34.3% | 0.00% | +50.0% |
| Q3 2020 | $1,090,260,000 | -24.7% | 4,401 | -19.8% | 0.00% | -33.3% |
| Q2 2020 | $1,448,688,000 | -83.5% | 5,486 | -88.2% | 0.00% | -83.3% |
| Q1 2020 | $8,787,939,000 | +67.2% | 46,345 | +93.6% | 0.02% | +80.0% |
| Q4 2019 | $5,254,630,000 | +216.5% | 23,938 | +182.1% | 0.01% | +233.3% |
| Q3 2019 | $1,660,456,000 | -83.2% | 8,486 | -82.1% | 0.00% | -85.0% |
| Q2 2019 | $9,870,751,000 | +246.3% | 47,344 | +229.8% | 0.02% | +233.3% |
| Q1 2019 | $2,850,185,000 | -71.4% | 14,355 | -79.2% | 0.01% | -75.0% |
| Q4 2018 | $9,978,010,000 | +218.8% | 68,947 | +349.6% | 0.02% | +380.0% |
| Q3 2018 | $3,130,231,000 | +192.7% | 15,336 | +112.2% | 0.01% | +150.0% |
| Q2 2018 | $1,069,383,000 | -27.3% | 7,228 | -25.8% | 0.00% | -33.3% |
| Q1 2018 | $1,471,583,000 | -34.9% | 9,743 | -44.2% | 0.00% | -25.0% |
| Q4 2017 | $2,262,202,000 | +4.4% | 17,462 | -2.6% | 0.00% | -20.0% |
| Q3 2017 | $2,167,558,000 | -7.2% | 17,930 | -9.8% | 0.01% | -28.6% |
| Q2 2017 | $2,335,900,000 | +65.2% | 19,880 | +42.9% | 0.01% | +75.0% |
| Q1 2017 | $1,414,155,000 | -13.9% | 13,912 | -12.9% | 0.00% | -50.0% |
| Q4 2016 | $1,642,504,000 | +71.4% | 15,973 | +82.5% | 0.01% | +100.0% |
| Q3 2016 | $958,454,000 | -59.6% | 8,753 | -58.4% | 0.00% | -63.6% |
| Q2 2016 | $2,372,004,000 | +237.0% | 21,034 | +182.4% | 0.01% | +266.7% |
| Q1 2016 | $703,890,000 | -42.7% | 7,447 | -45.4% | 0.00% | 0.0% |
| Q4 2015 | $1,227,960,000 | +65.6% | 13,644 | +70.1% | 0.00% | +50.0% |
| Q3 2015 | $741,529,000 | -2.4% | 8,020 | +3.9% | 0.00% | 0.0% |
| Q2 2015 | $759,893,000 | +432.8% | 7,717 | +442.7% | 0.00% | – |
| Q1 2015 | $142,613,000 | +50.0% | 1,422 | +38.2% | 0.00% | – |
| Q4 2014 | $95,080,000 | – | 1,029 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |